Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5192_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Dedications
- •Contributors
- •Acknowledgments
- •Preface
- •1 Basic science
- •1.1 Structure and function of the skin
- •Epidermis
- •Cellular biology of the epidermis
- •Dermal cells of importance
- •Structural components and cell biology of the dermis
- •1.2 Embryology
- •1.3 Wound healing
- •Dermis
- •1.4 Genetics
- •Basic cell biology of genome
- •Inheritance patterns
- •1.5 Ultraviolet light
- •Ultraviolet light (Fig. 1.8)
- •Minimal erythema dose
- •1.6 Immunology
- •Innate immunity
- •Adaptive immunity
- •1.6.2 Immunologic mediators
- •Cytokines
- •Pattern recognition receptors
- •Antimicrobial proteins (AMPs)
- •The complement system
- •B cells
- •T cells (majority of lymphocytes)
- •Innate lymphoid cells
- •NK cells
- •Mononuclear phagocytes
- •Langerhans cells
- •Dendritic cells
- •Mast cells
- •Eosinophils
- •Neutrophils
- •1.6.4 Major histocompatibility complex
- •1.7 Laboratory techniques
- •1.7.1 Tissue acquisition and processing
- •Polymerase chain reaction (PCR)
- •Quantitative reverse transcriptase PCR (qRT-PCR)
- •16S ribosomal RNA (rRNA) sequencing
- •DNA sequencing
- •RNA sequencing
- •Fluorescence in situ hybridization (FISH)
- •Immunohistochemistry (IHC)
- •Enzyme-linked immunosorbent assay (ELISA)
- •1.7.3 Cellular engineering and gene therapy
- •2 Dermatopharmacology
- •2.1 ANTIHISTAMINES
- •Mechanism
- •Other antihistamines
- •Introduction
- •Mucocutaneous
- •Systemic
- •Teratogenicity
- •Contraindications
- •Interactions
- •2.3 CORTICOSTEROIDS
- •Hypothalamic-pituitary-adrenal (HPA) axis suppression (Box 2.1)
- •Psychiatric changes
- •Contraindications
- •Pregnancy
- •Clinical use
- •Intramuscular CS
- •Pulse IV CS
- •Adalimumab
- •Certolizumab pegol
- •Golimumab
- •Indications
- •Ustekinumab
- •IL-17 inhibitors
- •IL-23 inhibitors
- •Spesolimab
- •Rituximab
- •IL-1 inhibitors
- •Omalizumab
- •Dupilumab
- •Lebrikizumab and tralokinumab
- •Nemolizumab
- •Vismodegib and sonidegib
- •Intralesional CS
- •Monitoring
- •2.4 IMMUNOMODULATORY AGENTS
- •Apremilast and other PDE-4 inhibitors
- •Janus Kinase (JAK) and Tyro inhibitors
- •Agents used in dermatology
- •Laboratory monitoring
- •Azathioprine
- •Important monitoring points
- •Cyclosporine
- •Important pharmacology points
- •Indications
- •Important monitoring points
- •Methotrexate
- •Important pharmacology points
- •Indications and contraindications
- •Important monitoring points
- •Important pharmacology points
- •Indications
- •Monitoring guidelines
- •Cytotoxic agents
- •Hydroxyurea
- •Cyclophosphamide
- •Chlorambucil
- •Antimalarial agents
- •Important pharmacology points
- •Indications
- •Dapsone
- •Important pharmacology points
- •Indications
- •Important monitoring points
- •Etanercept
- •MEK inhibitors (trametinib, cobimetinib, binimetinib)
- •Ipilimumab
- •PD-1 inhibitors (pembrolizumab, nivolumab, cemiplimab) and PD-L1 inhibitors (avelumab, atezolizumab)
- •Imatinib mesylate
- •Ibrutinib
- •Talimogene
- •Mechlorethamine hydrochloride
- •Brentuximab vedotin
- •Mogamulizumab
- •Romidepsin and vorinostat
- •2.6 ANTIMICROBIAL AGENTS
- •Topical antibacterial agents
- •Bacitracin
- •Benzoyl peroxide
- •Metronidazole
- •Azelaic acid
- •Systemic antibacterial agents
- •Penicillins
- •Polymyxin B
- •Neomycin
- •Mupirocin
- •Retapamulin
- •Gentamicin
- •Iodoquinol
- •Cephalosporins
- •Vancomycin
- •Macrolides
- •Fluoroquinolones
- •Tetracyclines
- •Clindamycin
- •Carbapenems
- •Linezolid
- •Daptomycin
- •Others
- •Antiviral agents
- •Acyclovir
- •Valacyclovir
- •Famciclovir and penciclovir
- •Foscarnet
- •Bleomycin
- •Podophyllin resin and podophyllotoxin
- •Cantharidin
- •Sinecatechins
- •5-Fluorouracil and imiquimod (discussed in section 2.5)
- •I. Azoles
- •Itraconazole
- •Fluconazole
- •Ketoconazole
- •Voriconazole
- •Posaconazole
- •Miconazole, clotrimazole, and econazole
- •Efnaconazole
- •Luliconazole
- •II. Allylamines/benzylamines
- •Terbinafne
- •Butenafne
- •IV. Ciclopirox olamine
- •VI. Nystatin
- •VIII. Tavaborole
- •Antiparasitic agents (Tables 2.7 and 2.8)
- •2.7 PHOTOTHERAPY
- •UVA modalities
- •Psoralen plus UVA (PUVA)
- •UVA-1 (340–400 nm)
- •UVB modalities
- •Extracorporeal photochemotherapy
- •Photodynamic therapy (PDT)
- •2.8 MISCELLANEOUS AGENTS
- •Sunscreens
- •Topical cosmetic agents
- •Bimatoprost
- •Brimonidine and oxymetazoline
- •Hydroquinone
- •Psychiatric agents
- •Antiandrogens and androgen inhibitors
- •Spironolactone
- •Finasteride and dutasteride
- •Combination oral contraceptive pills
- •Clascoterone
- •Calcipotriene and calcitriol
- •Attenuated androgens
- •Danazol and stanozolol
- •Colchicine
- •Potassium iodide
- •Thalidomide
- •Topical calcineurin inhibitors
- •Pimecrolimus and tacrolimus
- •Intravenous immunoglobulin (IVIG)
- •Glycopyrrolate
- •Oxybutynin
- •Botulinum toxin
- •Aluminum chloride
- •2.9 DRUG INTERACTIONS AND THE CYTOCHROME P-450 SYSTEM
- •Key points
- •CYP1A2
- •CYP2C9
- •CYP2D6
- •CYP3A4 (most relevant to dermatologists)
- •Classic CYP mnemonics
- •2.10 DRUG REACTIONS
- •Urticaria, angioedema, and anaphylaxis
- •Fixed drug eruption/Stevens-Johnson syndrome/toxic epidermal necrolysis
- •Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS)
- •Acute generalized exanthematous pustulosis (AGEP)
- •Photosensitive drug reactions
- •Drug-induced pigmentary changes
- •Bullous drug reactions, lichenoid drug eruptions, drug-induced connective tissue disease
- •Other drug eruptions
- •3 General dermatology
- •3.1 Papulosquamous dermatoses
- •3.2 Eczematous dermatoses
- •3.3 Interface dermatitis
- •Vacuolar interface dermatitis
- •Autoimmune connective tissue disease (AICTD)
- •Erythema multiforme (EM)
- •Stevens-johnson syndrome (SJS), and toxic epidermal necrolysis (TEN, lyell’s syndrome)
- •Pityriasis lichenoides
- •Fixed drug eruption (FDE)
- •Graft- versus- host disease (GVHD)
- •Lichenoid interface dermatitis
- •Lichen planus (LP)
- •Keratosis lichenoides chronica (KLC)
- •Erythema dyschromicum perstans (ashy dermatosis)
- •Lichenoid keratosis (benign lichenoid keratosis [BLK], LP-like keratosis)
- •Lichen nitidus
- •3.4 Blistering diseases
- •Pemphigus disease family
- •Pemphigus vulgaris (PV)
- •Pemphigus foliaceus (PF)
- •Paraneoplastic pemphigus (PNP)/paraneoplastic autoimmune multiorgan syndrome (PAMS)
- •Autoimmune subepidermal blistering diseases
- •Bullous pemphigoid (BP; pemphigoid)
- •Mucous membrane pemphigoid (MMP; cicatricial pemphigoid)
- •Linear IgA bullous dermatosis/chronic bullous disease of childhood (LABD/CBDC)
- •Epidermolysis bullosa acquisita
- •Bullous systemic lupus erythematosus
- •Dermatitis herpetiformis (duhring disease)
- •Inherited blistering diseases
- •Epidermolysis bullosa (see chapter 4)
- •Darier disease (keratosis follicularis)
- •Other blistering diseases
- •Lupus band test (LBT)
- •Lupus erythematosus
- •Chronic cutaneous lupus erythematosus (CCLE)
- •Subacute cutaneous lupus erythematosus
- •Acute cutaneous lupus erythematosus (ACLE)
- •Other rare cutaneous lupus variants
- •Systemic lupus erythematosus (SLE)
- •Drug-induced SLE (DI-SLE)
- •Lupus-related diseases
- •Other autoimmune connective tissue diseases and sclerosing dermopathies
- •Dermatomyositis (DM)
- •Sjögren’s syndrome
- •Relapsing polychondritis
- •Mixed connective tissue disease (MCTD)
- •Rheumatoid arthritis
- •Systemic-onset juvenile idiopathic arthritis (still’s disease)
- •Morphea (localized scleroderma)
- •Eosinophilic fasciitis (shulman syndrome)
- •Abnormalities of connective tissue
- •3.6 Granulomatous/histiocytic disorders
- •Non-infectious granulomas
- •Granuloma annulare (GA)
- •Annular elastolytic giant cell granuloma (actinic granuloma of O’Brien
- •Interstitial granulomatous dermatitis and arthritis (IGDA) and palisaded neutrophilic granulomatous dermatitis (PNGD)
- •Interstitial granulomatous drug eruption
- •Necrobiosis lipoidica (necrobiosis lipoidica diabeticorum, NLD)
- •Necrobiotic xanthogranuloma (NXG)
- •Cutaneous crohn’s disease
- •Sarcoidosis
- •Histiocytoses
- •Langerhans cell histiocytosis (LCH)
- •Non-langerhans cell histiocytoses (discussed in Table 3.23)
- •Malignant histiocytic disorders
- •3.7 Monoclonal gammopathies of dermatologic interest
- •3.8 Xanthomas
- •3.9 Urticaria and angioedema
- •3.10 Neutrophilic dermatoses
- •Amicrobial pustulosis of the folds
- •3.11 Eosinophilic disorders
- •Granuloma faciale
- •Eosinophilic folliculitis
- •Papuloerythroderma of ofuji
- •Wells’ syndrome (eosinophilic cellulitis)
- •Hypereosinophilic syndrome (HES)
- •3.12 Figurate erythemas
- •3.13 Follicular and eccrine/apocrine disorders
- •Acne variants
- •Acne fulminans
- •Acne conglobata
- •Solid facial edema in acne
- •Acne mechanica
- •Neonatal acne (neonatal cephalic pustulosis)
- •Infantile acne
- •Transverse nasal crease
- •Acne in setting of endocrinologic abnormality
- •Acne cosmetica
- •Pomade acne
- •Chloracne
- •Radiation acne
- •Acneiform eruptions
- •Drug-induced acne
- •Acne-associated syndromes
- •SAPHO (chronic recurrent multifocal osteomyelitis)
- •PAPA
- •HAIR-AN
- •Apert syndrome (acrocephalosyndactyly)
- •Rosacea
- •Epidemiology
- •Rosacea subtypes
- •Erythematotelangiectatic (vascular)
- •Phymatous
- •Ocular
- •Rosacea variants
- •Solid facial edema in rosacea (morbihan disease and rosacea lymphedema)
- •Pyoderma faciale (rosacea fulminans)
- •Granulomatous rosacea
- •Lupus miliaris disseminatus faciei
- •Folliculitis
- •Gram-negative folliculitis
- •Hot tub folliculitis
- •Eosinophilic folliculitis
- •Disseminate and recurrent infundibulofolliculitis
- •Viral-associated trichodysplasia
- •Pseudofolliculitis barbae
- •Acne keloidalis nuchae
- •Follicular occlusion tetrad (acne conglobata, hidradenitis suppurativa, dissecting cellulitis of the scalp, and pilonidal cyst)
- •Hidradenitis suppurativa (acne inversa)
- •Pilonidal cyst
- •Dissecting cellulitis of the scalp and acne conglobata (discussed in alopecia and acne sections)
- •Other diseases of eccrine and apocrine sweat glands
- •Hyperhidrosis
- •Hypohidrosis and anhidrosis
- •Miliaria
- •Bromhidrosis
- •Chromhidrosis
- •Fox-fordyce disease (apocrine miliaria)
- •3.14 Drug reactions
- •3.15 Photodermatoses and other physical dermatoses
- •Temperature-related dermatoses
- •Thermal burns
- •Erythema ab igne
- •Cold injuries
- •Photoaging
- •Polymorphous light eruption
- •Hydroa vacciniforme (see Chapter 4)
- •Actinic folliculitis
- •Chronic actinic dermatitis
- •Actinic prurigo (see chapter 4)
- •Solar urticaria
- •Mechanical injuries
- •3.17 Neurodermatology and psychodermatology
- •Cutaneous manifestations of psychiatric illness or self-induction
- •Delusions of parasitosis
- •Excoriation disorder (neurotic excoriations)
- •Factitial dermatitis/dermatitis artefacta
- •Gardner-diamond syndrome
- •Body dysmorphic disorder
- •Cupping/coining
- •Other neurocutaneous dermatoses
- •Scalp dysesthesia/burning scalp syndrome
- •Burning mouth syndrome
- •Brachioradial pruritus
- •Notalgia paresthetica
- •Meralgia paresthetica
- •Trigeminal trophic syndrome
- •Familial dysautonomia/riley-day syndrome
- •Auriculotemporal nerve syndrome (frey syndrome)
- •3.18 Palmoplantar keratodermas
- •3.19 Nutritional disorders in dermatology
- •3.21 Ulcers (Table 3.33)
- •3.22 Vasculitides, vasculopathies, and other vascular disorders
- •Subtypes of cutaneous small vessel vasculitis
- •Henoch-schonlein purpura (HSP)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Key features of adult HSP
- •Key features of childhood HSP
- •Treatment
- •Laboratory testing: See CSVV section
- •Pathology
- •Acute hemorrhagic edema of infancy (Fig 3.86)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Treatment
- •Urticarial vasculitis
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Laboratory testing
- •Treatment (Table 3.41)
- •Erythema elevatum diutinum
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Treatment
- •Mixed cryoglobulinemia (see cryoglobulinemia section)
- •Small to medium vessel vasculitis
- •Granulomatosis with polyangiitis (wegener)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Treatment
- •Microscopic polyangiitis (MPA)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Laboratory testing: See CSVV, especially:
- •Treatment
- •Eosinophilic granulomatosis with polyangiitis (churg-strauss syndrome)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation: Three classic stages (Table 3.47)
- •Pathology
- •Laboratory testing
- •Treatment
- •Medium vessel vasculitis
- •Subtypes: PAN and kawasaki’s disease
- •Polyarteritis nodosa
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Laboratory testing: See CSVV
- •Treatment
- •Kawasaki disease (acute febrile mucocutaneous lymph node syndrome)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation (Fig. 3.90)
- •Laboratory testing
- •Treatment
- •Key testing facts
- •Large vessel vasculitis
- •Subtypes: Temporal arteritis and Takayasu’s arteritis
- •Temporal arteritis (giant cell arteritis)
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Laboratory workup
- •Treatment
- •Takayasu’s arteritis
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Laboratory workup
- •Treatment
- •Summary of organ system involvement in various vasculitides (Table 3.49)
- •Cryoglobulinemias
- •Epidemiology
- •Thrombosis and thrombotic syndromes
- •Important subtypes
- •Calciphylaxis
- •Antiphospholipid syndrome
- •Epidemiology
- •Pathophysiology
- •Clinical presentation
- •Pathology
- •Treatment
- •Pathogenesis
- •Clinical presentation
- •Pathology
- •Treatment
- •Other vasculopathies (Table 3.51)
- •Other vascular disorders
- •Venous lake
- •Telangiectasia
- •Erythromelalgia
- •Livedo reticularis (LR)
- •Angiospastic macules (bier spots)
- •3.23 Panniculitides and lipodystrophies
- •3.24 Dermatoses of pregnancy
- •3.25 Hair, nail, and mucosal disorders
- •Non-scarring alopecia
- •Androgenetic alopecia
- •Trichotillomania
- •Alopecia areata
- •Temporal triangular alopecia
- •Congenital atrichia with papules
- •Cicatricial (scarring) alopecia
- •Central centrifugal cicatricial alopecia
- •Lichen planopilaris
- •Acne keloidalis nuchae
- •Dissecting cellulitis of the scalp (perifolliculitis capitis abscedens et suffodiens)
- •Folliculitis decalvans
- •Traction alopecia
- •Hair shaft abnormalities
- •Hypertrichosis and hirsutism
- •Hypertrichosis
- •Nail disorders
- •Mucosal disorders
- •3.26 Pigmentary disorders
- •Disorders of hypopigmentation and depigmentation
- •Vitiligo
- •Halo nevus
- •Chemical and physical agent-induced hypopigmentation
- •Idiopathic guttate hypomelanosis
- •Progressive macular hypomelanosis
- •Nevus anemicus
- •Pigmentary mosaicism
- •Hypomelanosis of ito
- •Nevus depigmentosus
- •Disorders of hyperpigmentation
- •Melasma
- •Erythema dyschromicum perstans (ashy dermatosis) discussed in Section 3.3
- •Lichen planus pigmentosus
- •Linear and whorled nevoid hypermelanosis
- •Prurigo pigmentosa
- •Familial progressive hyperpigmentation
- •Endocrinopathies
- •Pigmentary demarcation lines (aka futcher’s lines, voight lines, ito’s lines)
- •4 Pediatric dermatology
- •4.1 Neonatal dermatology
- •4.2 Viral exanthems and select infectious disorders of childhood
- •4.3 Inherited pigmentary disorders
- •Hypo-/depigmentation
- •Pigmentary mosaicism
- •Oculocutaneous albinism (OCA)
- •Silvery hair syndromes
- •Griscelli syndrome
- •Hermansky-Pudlak syndrome
- •Piebaldism
- •Waardenburg syndrome
- •Hyperpigmentation
- •McCune-Albright syndrome
- •Lentiginoses syndromes
- •Hereditary dyschromatoses
- •Dyschromatosis symmetrica hereditaria (acropigmentation of Dohi)
- •Dyschromatosis universalis hereditaria
- •Naegeli-Franceschetti-Jadassohn syndrome (NFJS)/dermatopathia pigmentosa reticularis (DPR)
- •4.4 Epidermolysis bullosa
- •4.5 Tumor syndromes
- •4.6 Vascular tumors, malformations, and related vascular disorders
- •Vascular tumors
- •Phace syndrome
- •LUMBAR/SACRAL syndrome
- •Multiple hemangiomas
- •Kasabach-Merritt phenomenon
- •Vascular malformations
- •Capillary malformations (CM)
- •Sturge-Weber syndrome (encephalotrigeminal angiomatosis)
- •Phakomatosis pigmentovascularis
- •Phakomatosis pigmentokeratotica
- •PIK3CA-related overgrowth spectrum (PROS)
- •Klippel-trenaunay syndrome
- •Macrocephaly capillary malformation syndrome
- •Cloves syndrome
- •Proteus syndrome
- •Beckwith-wiedemann syndrome
- •Diffuse capillary malformation with overgrowth (DCMO)
- •Venous malformations
- •Maffucci syndrome (enchondromas with multiple angiomas)
- •Blue rubber bleb nevus syndrome
- •Glomulovenous malformations (GVMs; previously termed “glomangiomas”)
- •Lymphatic malformations
- •Macrocystic lymphatic malformations (cystic hygroma)
- •Gorham-stout (disappearing bone) disease
- •Congenital lymphedema (hereditary congenital lymphedema, Nonne-Milroy syndrome)
- •Arteriovenous malformations
- •AVMs
- •Parkes-weber syndrome
- •Cobb syndrome (cutaneomeningospinal angiomatosis)
- •Other vascular disorders
- •4.7 Disorders of hair and nails
- •Pachyonychia congenita
- •Ectodermal dysplasias
- •Hypohidrotic ectodermal dysplasia (Christ-Siemens-Touraine syndrome)
- •Hidrotic ectodermal dysplasia (Clouston syndrome)
- •Ectodermal dysplasias due to p63 mutation
- •Schöpf-Schulz-Passarge syndrome
- •Other disorders
- •Rubinstein-Taybi syndrome
- •Parakeratosis pustulosa
- •Congenital malalignment of the great toenails
- •4.8 Inherited metabolic and nutritional disorders
- •4.9 Inherited connective tissue disorders
- •4.10 Autoinflammatory disorders (periodic fever syndromes)
- •4.12 Premature aging syndromes and DNA repair disorders
- •4.13 Primary immunodeficiency disorders with cutaneous manifestations
- •4.14 Disorders of cornification
- •Actinic prurigo
- •Diaper dermatitis
- •Juvenile plantar dermatosis
- •Acropustulosis of infancy
- •Trichorhinophalangeal syndrome
- •Midas syndrome (also MLS or microphthalmia with linear skin defects)
- •H syndrome
- •Cutaneous mastocytosis
- •Neutrophilic eccrine hidradenitis of childhood
- •5 Infectious diseases
- •5.1 Viral diseases
- •Herpes simplex virus (HHV-1/HSV-1 and HHV-2/HSV-2)
- •Varicella zoster virus (VZV; HHV-3)
- •Epstein-Barr virus (HHV-4)
- •Cytomegalovirus (HHV-5)
- •HHV-6 (Roseola infantum, exanthem subitum, sixth disease)
- •HHV-7
- •HHV-8
- •Poxviruses
- •Zika virus
- •Dengue virus
- •Viral hepatitides (Table 5.2)
- •Viral-associated trichodysplasia of immunosuppression
- •COVID-19
- •5.2 HIV/AIDS dermatology
- •5.3 Bacterial infections
- •Staphylococcal skin infections
- •Corynebacterial skin infections
- •Clostridium skin infections
- •Filamentous bacteria
- •Other gram-positive infections
- •Pseudomonas
- •Bartonella
- •Rickettsia
- •Other gram-negative skin infections
- •Borrelia
- •Nonvenereal (endemic) treponematoses
- •Syphilis
- •Cutaneous tuberculosis
- •Leprosy (hansen’s disease)
- •Atypical mycobacteria
- •Tinea versicolor (pityriasis versicolor)
- •Piedra
- •Tinea nigra
- •Sporotrichosis
- •Lobomycosis
- •Mycetoma (madura foot)
- •Chromoblastomycosis
- •Histoplasmosis
- •Blastomycosis (“north American blastomycosis”)
- •Coccidioidomycosis
- •Paracoccidioidomycosis (“South American blastomycosis”)
- •Candidiasis
- •Cryptococcosis
- •Aspergillosis
- •Fusarium
- •Penicilliosis
- •Zygomycosis (mucormycosis)
- •Phaeohyphomycosis
- •Protothecosis
- •Rhinosporidiosis
- •5.5 Parasites and other creatures
- •Parasitic infestations
- •Scabies
- •Lice
- •Tungiasis
- •Myiasis
- •Protozoa
- •Leishmaniasis
- •Toxoplasmosis
- •Helminths
- •Cutaneous larva migrans
- •Larva currens
- •Onchocerciasis (“river blindness”)
- •Loiasis
- •Filariasis
- •Swimmer’s itch and seabather’s eruption
- •Trichinosis
- •Dracunculiasis (guinea worm)
- •Gnathosomiasis
- •Cysticercosis
- •Cutaneous amebiasis
- •Free-living amoeba
- •Gi-associated amoeba
- •Bites and stings
- •Biting and stinging insects
- •Arachnids (ticks, mites, spiders, and scorpions)
- •Millipedes and centipedes
- •Snake bites
- •6 Neoplastic dermatology
- •Neoplastic dermatology
- •6.1 Keratinocytic neoplasms
- •Premalignant/malignant
- •Actinic keratosis (AK)
- •Bowen’s disease (squamous cell carcinoma in situ)
- •Invasive cutaneous squamous cell carcinoma (cSCC, “SCC”)
- •Verrucous carcinoma
- •Keratoacanthoma
- •Basal cell carcinoma
- •6.2 Cysts
- •6.3 Melanocytic neoplasms
- •6.4 Adnexal neoplasms and hamartomas
- •Comparative dermatopathologic features of sweat gland neoplasms for board exam purposes
- •Poroma (classic juxtaepidermal type)
- •Hidroacanthoma simplex
- •Dermal duct tumor
- •Hidradenoma
- •Spiradenoma
- •Cylindroma
- •Syringoma
- •Mixed tumor (MT; “chondroid syringoma”)
- •Hidradenoma papilliferum (HPAP)
- •Syringocystadenoma papilliferum (SPAP, SCAP)
- •Papillary eccrine adenoma (PEA)
- •Tubular apocrine adenoma (TAA)
- •Porokeratotic eccrine ostial and dermal duct nevus
- •Microcystic adnexal carcinoma (MAC)
- •Aggressive digital papillary adenocarcinoma (ADPA)
- •Adenoid cystic carcinoma (ACC)
- •6.5 Hair follicle neoplasms/hamartomas
- •Folliculo-sebaceous-apocrine hamartomas
- •Trichofolliculoma
- •Fibrofolliculoma
- •Nevus sebaceus
- •Neoplasms with follicular germinative differentiation
- •Trichoepithelioma
- •Neoplasms with follicular matrix differentiation
- •Pilomatricoma (calcifying epithelioma of malherbe)
- •Neoplasms with follicular sheath (trichilemmal) differentiation
- •Trichilemmoma
- •Desmoplastic trichilemmoma (DTL)
- •Tumor of the follicular infundibulum (TFI)
- •Trichoadenoma (TA; of Nikolowski)
- •Proliferating pilar (trichilemmal) tumor
- •6.6 Sebaceous proliferations
- •6.7 Neural neoplasms
- •6.8 Smooth muscle neoplasms
- •6.9 Hematolymphoid neoplasms
- •6.10 Fibrohistiocytic neoplasms
- •Multinucleate cell angiohistiocytoma
- •Nodular fasciitis
- •Fibrous hamartoma of infancy
- •Giant cell tumor of tendon sheath (tenosynovial giant cell tumor)
- •Connective tissue nevus (collagenoma and elastoma)
- •6.11 Vascular proliferations
- •Benign vascular lesions
- •Vascular malformation (includes “port wine stain,” “cavernous hemangioma” old terminology)
- •Intravascular papillary endothelial hyperplasia (masson tumor, pseudoangiosarcoma)
- •Angiokeratoma
- •Infantile hemangioma
- •Pyogenic granuloma (lobular capillary hemangioma)
- •Epithelioid hemangioma (angiolymphoid hyperplasia with eosinophils, ALHE)
- •Targetoid hemosiderotic lymphatic malformation (hobnail hemangioma, targetoid hemosiderotic hemangioma)
- •Tufted angioma
- •Glomeruloid hemangioma
- •Glomus tumor/glomangioma
- •Borderline vascular neoplasms
- •Kaposiform hemangioendothelioma
- •Kaposi sarcoma (KS)
- •Other borderline vascular neoplasms (rare; not commonly tested)
- •High-grade malignant vascular neoplasms
- •Angiosarcoma
- •Vascular neoplasm associations
- •6.12 Neoplasms of adipocytic lineage
- •6.13 Dermoscopy
- •Seborrheic keratosis
- •Actinic keratosis
- •Basal cell carcinoma
- •Squamous cell carcinoma in situ
- •Squamous cell carcinoma
- •Ink spot lentigo
- •Vascular lesions (e.g., cherry angiomas)
- •Hemorrhage
- •Porokeratosis
- •Sebaceous hyperplasia
- •Dermoscopic patterns of melanocytic lesions
- •7 Dermatopathology
- •7.1 Essential concepts in dermatopathology
- •7.2 High-yield dermatopathology diagnoses at a glance
- •7.3 High-yield dermatopathology differential diagnoses
- •8 Dermatologic surgery
- •8.1 Surgical anatomy
- •8.2 Local anesthetics and perioperative pain control
- •8.3 Surgical instruments and needles
- •8.4 Suture techniques
- •8.5 Wound closure materials
- •8.7 Electrosurgery
- •8.8 Cryosurgery
- •8.9 Excisions
- •8.10 Mohs surgery
- •8.11 Flaps
- •8.12 Grafts
- •8.13 Surgical complications and measures to avoid them
- •8.14 Scar improvement
- •8.15 Nail surgery
- •8.16 Wound dressings
- •9 Cosmetic dermatology
- •9.1 Lasers

Acknowledgments
Our thanks to Dr. Christopher Sayed, Dr. Julia Lehman, Dr. Phillip Hochwalt, and Dr. Anwar Qais
Saadoon as they each contributed photos to the cover.
We would also like to thank Elsevier as well as our terric Section Editors for making this book
possible.
ix

Preface
Purpose of this book
We envision this book serving as a comprehensive review for
dermatology residents and practicing dermatologists. We
hope that the book is used not only in the United States, but
all over the world.
How the book should be used
The book can be used in many ways:
• As a resource for practicing dermatologists preparing for
recertication examinations or simply as a quick reference.
• As a resource for dermatology residents preparing for
board examinations, in-service examinations, or simply as
a quick reference (it could even be used throughout
residency as a place to compile notes and facts learned
from reading textbooks and journal articles, much the way
First Aid
©
was used during medical school).
How the book should NOT be used
There is NO substitution for reading textbooks and journal
articles during residency. This book should serve as a review or
a syllabus of dermatology, but should not take the place of
textbooks and original literature. Many great resources to truly
learn dermatology exist—our favorites are Dermatology (commonly referred to as “Bolognia”), Andrews’ Diseases of the Skin,
Comprehensive Dermatologic Drug Therapy (commonly referred
to as “Wolverton”), The Requisites in Dermatology Series (particularly dermatopathology and dermatologic surgery), Practi-
cal Dermatopathology (commonly referred to as “Rapini”), and
Hurwitz Clinical Pediatric Dermatology.
Other information
Please remember that space was limited for this book, as it is
for all books—we had to make important choices to leave
certain information out of the book.
We are extremely grateful to the authors and editors of the
textbooks listed above, as well as those of McKee’s Pathology of
the Skin and Weedon’s Skin Pathology, as nearly all of the gures
came from these resources.
Despite reading and re-reading this text many times, we
imagine that some errors may have snuck by. We encourage
you to email us at reviewofdermatology@gmail.com with any
errors or suggestions so we can correct these for our third edition. Please also email us if you have ideas to improve the
book or would like to contribute to future editions.
x

Contents
1 BASIC SCIENCE 1
Linda T. Doan and Tiffany C. Scharschmidt
1.1 Structure and Function of the Skin 1
1.2 Embryology 13
1.3 Wound Healing 13
1.4 Genetics 15
1.5 Ultraviolet Light 17
1.6 Immunology 18
1.7 Laboratory Techniques 28
2 DERMATOPHARMACOLOGY 39
Alexander Maley and Ali Alikhan
2.1 Antihistamines 39
2.2 Retinoids 40
2.3 Corticosteroids 42
2.4 Immunomodulatory Agents 46
2.5 Oncologic Agents in Dermatology 54
2.6 Antimicrobial Agents 57
2.7 Phototherapy 65
2.8 Miscellaneous Agents 67
2.9 Drug Interactions and the Cytochrome
P-450 System 70
2.10 Drug Reactions 71
3 GENERAL DERMATOLOGY 79
Christopher Sayed, Ali Alikhan, Olayemi Sokumbi,
Anand Rajpara, and Julia S. Lehman
3.1 Papulosquamous Dermatoses 79
3.2 Eczematous Dermatoses 86
3.3 Interface Dermatitis 96
3.4 Blistering Diseases 107
3.5 Connective Tissue Disease (CTD)
and Sclerosing Dermopathies 119
3.6 Granulomatous/Histiocytic Disorders 149
3.7 Monoclonal Gammopathies of
Dermatologic Interest 161
3.8 Xanthomas 164
3.9 Urticaria and Angioedema 166
3.10 Neutrophilic Dermatoses 169
3.11 Eosinophilic Disorders 172
3.12 Figurate Erythemas 173
3.13 Follicular and Eccrine/Apocrine Disorders 176
3.14 Drug Reactions 184
3.15 Photodermatoses and Other Physical
Dermatoses 184
3.16 Amyloidoses 188
3.17 Neurodermatology and Psychodermatology 189
3.18 Palmoplantar Keratodermas 192
3.19 Nutritional Disorders in Dermatology 192
3.20 Depositional and Calcication
Disorders Not Discussed Elsewhere 194
3.21 Ulcers 194
3.22 Vasculitides, Vasculopathies,
and Other Vascular Disorders 194
3.23 Panniculitides and Lipodystrophies 210
3.24 Dermatoses of Pregnancy 212
3.25 Hair, Nail, and Mucosal Disorders 212
3.26 Pigmentary Disorders 220
4 PEDIATRIC DERMATOLOGY 229
Brea Prindaville and Jennifer J. Schoch
4.1 Neonatal Dermatology 229
4.2 Viral Exanthems and Select Infectious
Disorders of Childhood 229
xi

Contents
4.3 Inherited Pigmentary Disorders 240
4.4 Epidermolysis Bullosa 244
4.5 Tumor Syndromes 248
4.6 Vascular Tumors, Malformations,
and Related Vascular Disorders 250
4.7 Disorders of Hair and Nails 255
4.8 Inherited Metabolic and Nutritional
Disorders 258
4.9 Inherited Connective Tissue Disorders 263
4.10 Autoinammatory Disorders (Periodic
Fever Syndromes) 269
4.11 Neurocutaneous Syndromes 271
4.12 Premature Aging Syndromes and DNA
Repair Disorders 275
4.13 Primary Immunodeciency Disorders
With Cutaneous Manifestations 278
4.14 Disorders of Cornication 278
4.15 Miscellaneous Pediatric Dermatologic
Disorders 281
5 INFECTIOUS DISEASES 293
Ali Alikhan and Thomas L.H. Hocker
5.1 Viral Diseases 293
5.2 HIV/AIDS Dermatology 301
5.3 Bacterial Infections 304
5.4 Fungal Diseases 322
5.5 Parasites and Other Creatures 329
6 NEOPLASTIC DERMATOLOGY 337
Monisha N. Dandekar, Roberto A. Novoa, and
Phillip C. Hochwalt
7 DERMATOPATHOLOGY 391
Julia S. Lehman and Roberto A. Novoa
7.1 Essential Concepts in Dermatopathology 391
7.2 High-Yield Dermatopathology Diagnoses
at a Glance 415
7.3 High-Yield Dermatopathology Differential
Diagnoses 415
8 DERMATOLOGIC SURGERY 443
Phillip C. Hochwalt and Thomas L.H. Hocker
8.1 Surgical Anatomy 443
8.2 Local Anesthetics and Perioperative
Pain Control 450
8.3 Surgical Instruments
and Needles 454
8.4 Suture Techniques 455
8.5 Wound Closure Materials 455
8.6 Antisepsis and Sterilization 458
8.7 Electrosurgery 458
8.8 Cryosurgery 461
8.9 Excisions 461
8.10 Mohs Surgery 463
8.11 Flaps 463
8.12 Grafts 472
8.13 Surgical Complications
and Measures to Avoid Them 473
8.14 Scar Improvement 476
8.15 Nail Surgery 477
8.16 Wound Dressings 479
Neoplastic Dermatology 337
6.1 Keratinocytic Neoplasms 337
6.2 Cysts 343
6.3 Melanocytic Neoplasms 344
6.4 Adnexal Neoplasms
and Hamartomas 351
6.5 Hair Follicle Neoplasms/Hamartomas 359
6.6 Sebaceous Proliferations 363
6.7 Neural Neoplasms 364
6.8 Smooth Muscle Neoplasms 367
6.9 Hematolymphoid Neoplasms 368
6.10 Fibrohistiocytic Neoplasms 373
6.11 Vascular Proliferations 378
6.12 Neoplasms of Adipocytic Lineage 382
6.13 Dermoscopy 382
xii
9 COSMETIC DERMATOLOGY 481
Ronda S. Farah
9.1 Lasers 481
9.2 Botulinum Toxin 488
9.3 Dermal Fillers 491
9.4 Liposuction and Fat Reduction 494
9.5 Sclerotherapy and Vein Management 494
9.6 Cosmeceuticals, Nutraceuticals,
and Other Supplements 497
9.7 Hair Transplantation 498
9.8 Chemical Peels 498
9.9 Other Esthetic Procedures and Scales 500

Contents
10 CUTANEOUS MANIFESTATIONS OF
INTERNAL DISEASE AND
METASTASES 505
Nada Elbuluk
10.1 Cardiovascular/Cardiopulmonary 505
10.2 Endocrine 512
10.3 Gastroenterology 514
10.4 Neurology 519
10.5 Renal 519
10.6 Paraneoplastic Syndromes 520
11 EPIDEMIOLOGY, STATISTICS,
STUDY DESIGN, PUBLIC HEALTH
PRINCIPLES, AND BILLING 527
Jonathan I. Silverberg and Alexander Maley
11.1 Epidemiologic Denitions 527
11.2 Epidemiologic Principles 527
11.3 Types of Studies and Their Limitations 528
11.4 Types of Bias 530
11.5 Maintenance of Certication for
the American Board of Dermatology 530
11.6 Billing 530
Index 535
xiii

This page intentionally left blank

1
Basic Science
Linda T. Doan and Tiffany C. Scharschmidt
CONTENTS LIST
1.1 STRUCTURE AND FUNCTION OF THE SKIN
1.2 EMBRYOLOGY
1.3 WOUND HEALING
1.4 GENETICS
1.5 ULTRAVIOLET LIGHT
1.6 IMMUNOLOGY
1.7 LABORATORY TECHNIQUES
1.1 STRUCTURE AND FUNCTION OF THE SKIN
• Functions: interfaces with environment, collects sensory
data, protects against infection and chemical penetration,
temperature regulation, water retention, and excretion of
drugs/waste
• Composed of three layers: epidermis, dermis, and
subcutis
Epidermis
Cellular biology of the epidermis
• Squamous epithelium composed of keratinocytes
connected by desmosomes, adherens junctions, tight
junctions, and gap junctions (Table 1.1)
■
Intercellular junctions
Desmosomes: primary keratinocyte intercellular
junction
◆ Provide structure and integrity to the epidermis
by anchoring/attaching to keratins
◆ Components (see Table 1.1)
◆ Desmocollins, desmogleins, and other cadherins
are calcium-dependent
Adherens junctions: also mediate tight intercellular
binding (Fig. 1.1)
◆ Anchor/attach to actin laments
◆ Consist of a-catenin (cytoplasmic), b-catenin
(cytoplasmic), plakoglobin (cytoplasmic), and
classic cadherins (E and P; transmembrane)
Tight junctions: composed of claudins and
occludin; form tight seal against water loss in
granular layer
Gap junctions: facilitate intercellular communication;
composed of connexons (tubular channels composed
of six connexins)
• Cells originate in the cuboidal basal layer and atten out
as they ascend to the surface—four to ve layers/strata
(deep to supercial): s. basale, s. spinosum, s.
granulosum, s. lucidum (only on palmoplantar surfaces),
and s. corneum (Table 1.2)
• An increasing total (intra- and extracellular) calcium
gradient is present in the epidermis, with low levels of
calcium in the stratum basale and increasingly higher
levels of calcium toward the stratum granulosum
■
Multiple calcium-dependent processes in the epidermis
are driven by the calcium gradient including
keratinocyte maturation, desmosome formation,
transglutaminase function, cleavage of prolaggrin, and
extrusion and degradation of keratohyalin granules
• Stratum basale: mitotically active cuboidal cells from
which the upper layers of the epidermis are derived
■
Attached to dermis by hemidesmosomes
■
Cellular proliferation stimulated by various factors,
including trauma and UV (↑ ornithine decarboxylase
expression is associated with (a/w) proliferative
states)
Ornithine decarboxylase is inhibited by
corticosteroids, retinoids, and vitamin D3
■
10% of cells in the basal layer are stem cells, which give
rise to other stem cells, and to transient amplifying
cells that will replicate for a few cycles until they
1

CHAPTER 1 • Basic Science
Table 1.1 Intercellular Junction Proteins
Junction Type Protein Family Protein Disease State
Desmosome
Anchor/attach to keratin filaments
Desmosome and adherens junction Armadillo (catenin)
Adherens junction
Attach to actin laments
Gap junction
Facilitate intercellular communication.
Important for calcium regulation
PNP, paraneoplastic pemphigus; PV, pemphigus vulgaris; PPK, palmoplantar keratosis; SSSS, staph scalded skin syndrome; SPD, subcorneal pustular derma-
tosis; KID, keratosis ichthyosis deafness syndrome
Cadherin (transmembrane)
Cadherins are calcium-
dependent transmembrane
proteins.
Plakin (cytoplasmic) Desmoplakin Carvajal syndrome
Armadillo (cytoplasmic) Plakophilin Ectodermal dysplasia with skin fragility
(cytoplasmic)
Cadherin (transmembrane) E-Cadherin Somatic mutations in many neoplasms
Armadillo (cytoplasmic)
Connexin (transmembrane) Connexin 26 (GJB2) Vohwinkel syndrome, KID syndrome, Bart-Pumphrey
Desmoglein 1 Autoimmune: pemphigus foliaceus, PNP, PV (mucocutane-
Desmoglein 3 Pemphigus vulgaris (mucosal-predominant and
Desmoglein 4 Monilethrix (autosomal recessive form), autosomal
Desmocollin 1 IgA pemphigus (SPD type)
Desmocollin 2 Carvajal-like phenotype in one family
Desmocollin 3 Hypotrichosis
Plakoglobin Naxos syndrome
b-Catenin
Connexin 30 (GJB6) Hidrotic ectodermal dysplasia
Connexin 30.3 (GJB 4) Erythrokeratoderma variabilis
Connexin 31 (GJB 3) Erythrokeratoderma variabilis
ous form), IgA pemphigus (intraepidermal neutrophilic type)
Inherited: striate PPK
Infectious: bullous impetigo and SSSS
mucocutaneous forms), PNP, IgA pemphigus
(intraepidermal neutrophilic type)
recessive hypotrichosis
Somatic mutations in many neoplasms, including
pilomatricomas; also may be seen in myotonic
dystrophy and Rubinstein-Taybi
syndrome, PPK with deafness; also common in non-
syndromic deafness!
differentiate and move upward, eventually
desquamating
■
Transit time from basal layer to stratum corneum 5 14
days; transit through the stratum corneum/
desquamation 5 14 days (total 5 28 days from basal
layer to desquamation)
• Stratum spinosum: named for the “spiny” appearance
of intercellular desmosomal connections on
microscopy
■
Contains multiple types of intercellular junctions
■
Terminal keratinocyte differentiation 2° to ↑ calcium
in suprabasal epidermis
■
Odland bodies (lamellar granules) are produced by
Golgi bodies in spinous layer
Primarily contain ceramide (most important
lipid involved in epidermal barrier function),
along with glycoproteins, glycolipids, and
phospholipids
Are specialized lysosomes that exert most of their
action in the stratum corneum, by discharging
ceramides and other lipids into the extracellular
space of the junction between the stratum
granulosum and stratum corneum → ceramides
help form the cornied cell envelope (see below),
and eventually replace the cell membrane
• Stratum granulosum: attened cells with prominent
basophilic keratohyalin granules, which contain
prolaggrin (converted to laggrin at the junction of
stratum granulosum and stratum corneum), loricrin,
keratin intermediate laments, and involucrin
■
Cells begin to lose nuclei, but keep overall structure
■
Cornied cell envelope production primarily takes
place in the granular layer (Fig. 1.2)
Cross-linked protein and lipid structure encased in
extracellular lipids forming a strong polymer that
eventually replaces the plasma membrane
◆ Process starts with envoplakin, periplakin, and
involucrin scaffolding along the inner cell
membrane (which is eventually replaced by
ceramides from lamellar granules)
◆ Further reinforcement by cross-linking loricrin
(a major component of cornied envelope, rst
appears in granular layer; mutated in Vohwinkel
syndrome variant lacking deafness), small
proline-rich proteins, keratin, and laggrin
◆ Cross-linking occurs via transglutaminase 1 →
g-glutamyl lysine isopeptide bonds (Boards
factoids: TG-1 is mutated in lamellar ichthyosis;
TG-3 is antigenic target in dermatitis herpetiformis)
◆ Other components include envoplakin (helps
connect desmosomes to cornied envelope),
periplakin, elan, and others
◆ Outer surface of the cornied envelope is
ultimately surrounded by lipids (primarily
ceramide) 5 cornied lipid envelope
◆ Ultimately provides strong water-impermeable
outer barrier
• Stratum corneum: outermost layer, which serves as a
mechanical barrier between the epidermis and the
environment
2

THE ADHERENS JUNCTION AND DESMOSOME
A B
Actin
Intercellular space
Actin
PG
α
α
β
NC
Cad
Cad
Cad
Cad
PG
Cad
Cad
Cad
Cad
α
CN
α
β
Keratin
PG
DP
PP
DP
PG
Intercellular space
NC
Dsc
Dsg
Dsc
Dsg
Dsg
Dsc
Dsg
Dsc
Cytoplasm
Plasma membrane
Classic cadherin (Cad)
Plakoglobin (PG)
β-catenin (β)
α-catenin (α)
Fig. 1.1 The adherens junction and desmosome. (A) The adherens junction complex contains classic cadherins as transmembrane constituents, and a-catenins, bcatenins, and plakoglobin as cytoplasmic constituents. A classic cadherin is directly coupled through its cytoplasmic tail to b-catenin or plakoglobin, which in turn is
linked to b-catenin, which binds to actin. (B) The desmosome complex includes desmogleins and desmocollins as transmembrane constituents, and plakoglobin,
plakophilin, and desmoplakin as cytoplasmic constituents. Desmogleins and desmocollins associate with plakoglobin, which in turn binds to desmoplakin and links
keratin to the membrane. C, Carboxy-terminus. N, amino-terminus. (From Amagai M. Pemphigus. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. 4th ed.
Philadelphia: Elsevier; 2018:494–509.)
Desmoglein (Dsg)
Desmocollin (Dsc)
Plakoglobin (PG)
Plakophilin (PP)
Desmoplakin (DP)
Keratin
PG
DP
PP
DP
CN
PG
1.1 Structure and Function of the Skin
3

CHAPTER 1 • Basic Science
Table 1.2 Layers of the Epidermis
Epidermal Layer Stage of Maturation Products of Significance Associated Diseases
S. basale 10% of cells in basal layer are stem cells Keratin 5/14 Epidermolysis bullosa simplex
S. spinosum Terminal keratinocyte differentiation secondary to
↑ intracellular calcium
S. granulosum Cells lose nuclei, flatten, produce keratohyalin
granules (KHG) which contributes to the cornified
cell envelope which forms beginning in this layer
S. corneum Anucleate, protein-rich corneocytes
Keratin 1/10 Epidermolytic ichthyosis
Odland bodies (lamellar granules)
Contains ceramides
KHG which contain profilaggrin,
loricrin, keratin IF, and involucrin
Flegel’s and Harlequin’s ichthyosis are
2° to ↓ lamellar granules.
X-Linked ichthyosis 2° to absent ste-
roid sulfatase in lamellar granules
Ichthyosis vulgaris (laggrin)
Atopic dermatitis (laggrin)
Vohwinkel without deafness (loricrin)
■
Composed primarily of protein-rich corneocytes
(“bricks”; normally contain NO nuclei; keratin
laments attached to cornied envelope) embedded in
a lipid matrix (“mortar,” cornied lipid envelope)
■
Serves as a barrier to water loss (conditions that perturb
the skin barrier → ↑ transepidermal water loss) and
toxins/infectious agents
Epidermal cells of importance
• Keratinocytes: the primary cells of the epidermis;
responsible for producing proteins (e.g., keratin laments)
and lipids important for barrier function
■
Keratins: intermediate laments that comprise the
primary cytoskeleton of the epidermis (Table 1.3)
Type I keratins: low molecular weight; acidic; K9-
28, K31-40 (hair keratins); chromosome 17
Type II keratins: high molecular weight; basic; K1-
8, K81-86 (hair keratins); chromosome 12
Basic structure is an a-helical rod domain
(consisting of heptad amino acid repeats) divided
into four segments (1A, 1B, 2A, and 2B) that are
interrupted by three non-helical segments
(“linkers”)
Functional unit consists of heterodimers of type I
and type II laments that form tetramers and
ultimately laments
Anchored to plasma membrane by desmosomes
40 to 70 kD
■
Keratinocytes produce IL-1, IL-6, IL-8, IL-10, IL-12, and
TNF-a, among others
■
Keratinocytes respond to IL-2, IL-4, IL-13, IL-22, and
TNF-a, among others
• Melanocytes: Neural crest-derived, melanin-producing
cells; dendritic morphology; found in the stratum basale
in1:10 ratio with keratinocytes (when viewed in twodimensional plane)
■
c-kit activation is needed for melanocyte
development/migration; piebaldism occurs as a result
of c-kit loss → impaired melanocyte migration and
proliferation; c-kit mutations are a/w mucosal and
acral melanoma
■
Each melanocyte interfaces with 36 keratinocytes
when analyzed three-dimensionally (epidermal
melanin unit)
■
Melanin is produced in melanosomes (lysosome-type
organelles) from its precursor, tyrosine, through a
multistep enzymatic process involving tyrosinase
(copper-dependent enzyme)
Tyrosine
(tyr osinase -depend ent ste p)
→ DOPAquinone →
(tyr osinase -depend ent ste p)
→ DOPA
pheomelanin (yellow/red; made by round
melanosomes) or eumelanin (black/brown; made
by elliptical melanosomes)
Melanosomes are transported along the dendritic
processes and transferred to keratinocytes through
phagocytosis of dendrite tips
Racial variation in pigmentation: identical
melanocyte density in dark- and light-skinned
individuals; melanosomes in darker-skinned
individuals are larger, darker (↑ melanin), more
stable, and are transferred individually (vs.
smaller, lighter, less stable, and clustered
melanosomes in lighter-skinned individuals)
Melanin production is stimulated by melanocytestimulating hormone (MSH) and ACTH activity on
MC1-R on melanocytes; also stimulated through
various pathways induced by UV radiation
SOX10 is a transcription factor that controls
melanocyte differentiation
MC1-R loss of function mutations → ↑
pheomelanin:eumelanin ratio (phenotype 5 red
hair/fair skin, ↑ risk of melanoma)
Melanin absorbs UV → protects against UV-induced
mutations
UV exposure → biphasic tanning response:
immediate tanning (from oxidation and
redistribution of existing melanin) and delayed
tanning (occurs with new melanin synthesis,
melanocytic proliferation, increased transfer of
melanin from melanocyte to keratinocyte). (See
Section 1.5 for discussion on roles of UVA and UVB
in tanning).
■
Other high-yield examination facts:
Defects in enzymes required to convert tyrosine to
melanin → oculocutaneous albinism; OCA1
(Tyrosinase), OCA2 (P gene), OCA3 (TRP-1)
Defects in packaging of melanosome-specic
proteins → Hermansky-Pudlak syndrome (HPS1 .
HPS3 . other gene mutations)
Defects in lysosome and melanosome trafcking to
dendrites → Griscelli (MYO5A, RAB27A, and MLPH
mutations) and Chédiak-Higashi syndrome (LYST
mutations)
4
Соседние файлы в папке Библиотека им академика М.И. Перельмана
